COMPARATIVE EFFICACY OF INTRACORONARY VERAPAMIL AND ADRENALINE IN MANAGING CORONARY NO-REFLOW DURING PRIMARY PCI IN STEMI PATIENTS AT A TERTIARY CARE HOSPITAL
DOI:
https://doi.org/10.54112/bcsrj.v2024i1.957Keywords:
Adrenaline, Verapamil, Myocardial infarction, Coronary No-reflow, TIMI, MBGAbstract
Coronary No-Reflow (CNR) is a significant complication during Primary Percutaneous Coronary Intervention (PPCI) for ST-Elevation Myocardial Infarction (STEMI), often leading to poor clinical outcomes. Management strategies for CNR include various pharmacological agents, among which intracoronary verapamil and intracoronary adrenaline are commonly used alongside Glycoprotein IIb/IIIa inhibitors. Objective: This study aims to compare the effectiveness of intracoronary verapamil versus intracoronary adrenaline, alongside Glycoprotein IIb/IIIa inhibitors, in managing Coronary No-Reflow (CNR) during Primary Percutaneous Coronary Intervention (PPC1) for STEMI patients. Methodology: This randomized-control-trial was conducted at the Department of Cardiology, MTI Lady Reading Hospital Peshawar, Pakistan, from May 2023 to April 2024. Fifty patients diagnosed with CNR during PPC1 were randomised into two groups: adrenaline and verapamil. The primary outcome measures were TIMI Flow Grade (TFG) and Myocardial Blush Grade (MBG) immediately post-intervention. In contrast, secondary outcomes included Major Adverse Cardiovascular Events (MACE), myocardial infarction, stroke, target vessel revascularisation, mortality, and Left Ventricular Ejection Fraction (LVEF) assessed at baseline and one-month follow-up. Statistical analyses were performed using IBM SPSS version 20, with significance at P<0.05. Results: Baseline characteristics, procedural details, and initial TIMI flow grades were similar between groups. Adrenaline achieved universal TIMI 3 flow compared to 84% with verapamil (p=0.049), but no significant differences were noted in myocardial blush grades. Adrenaline led to significantly higher follow-up LVEF (45.0 ± 9.0 vs. 39.0 ± 9.0, p=0.027) and a more significant percentage change in LVEF (20.97% vs. 8.94%, p=0.042) than verapamil. Adverse event rates were comparable except for lower MACE incidence at 30 days with adrenaline (8.0% vs. 24.0%, p=0.039). Conclusion: Adrenaline notably enhanced TIMI 3 flow rates, improved left ventricular ejection fraction, and decreased significant adverse cardiovascular events at 30 days compared to verapamil. These findings suggest that adrenaline may be a superior option for improving coronary blood flow and early clinical outcomes in this patient population.
Downloads
References
Saleh M, Ambrose JA. Understanding myocardial infarction. F1000Research. 2018;7.
Nepper-Christensen L, Lønborg J, Høfsten DE, Ahtarovski KA, Bang LE, Helqvist S, et al. Benefit from reperfusion with primary percutaneous coronary intervention beyond 12 hours of symptom duration in patients with ST-segment–elevation myocardial infarction. Circulation: Cardiovascular Interventions. 2018;11(9):e006842.
Pantea-Roșan LR, Pantea VA, Bungau S, Tit DM, Behl T, Vesa CM, et al. No-reflow after PPCI—A predictor of short-term outcomes in STEMI patients. Journal of clinical medicine. 2020;9(9):2956.
Ndrepepa G, Kastrati A. Coronary No-Reflow after Primary Percutaneous Coronary Intervention—Current Knowledge on Pathophysiology, Diagnosis, Clinical Impact and Therapy. Journal of Clinical Medicine. 2023;12(17):5592.
Kammler J, Kypta A, Hofmann R, Kerschner K, Grund M, Sihorsch K, et al. TIMI 3 flow after primary angioplasty is an important predictor for outcome in patients with acute myocardial infarction. Clinical Research in Cardiology. 2009;98:165-70.
Rehman A-u, Malik J, Javed N, Iftikhar I, Sharif H. Myocardial blush grade: a determinant of left ventricular ejection fraction and adverse outcomes in STEMI. Scottish Medical Journal. 2021;66(1):34-9.
Blanchart K, Heudel T, Ardouin P, Lemaitre A, Briet C, Bignon M, et al. Glycoprotein IIb/IIIa inhibitors use in the setting of primary percutaneous coronary intervention for ST elevation myocardial infarction in patients pre‐treated with newer P2Y12 inhibitors. Clinical cardiology. 2021;44(8):1080-8.
Bendary A, Salem M, El-Sayed A, Al-Kady H, Khamis A, Ebaid H. Intracoronary Pharmacotherapy (Verapamil-Epinephrine-Adenosine) for Prevention of No Reflow during Primary Percutaneous Coronary Intervention in Patients with ST Elevation Myocardial Infarction. Benha Journal of Applied Sciences. 2023;8(8):1-11.
Khan KA, Qamar N, Saghir T, Sial JA, Kumar D, Kumar R, et al. Comparison of intracoronary epinephrine and adenosine for no-reflow in normotensive patients with acute coronary syndrome (COAR trial). Circulation: Cardiovascular Interventions. 2022;15(2):e011408.
Skelding KA, Goldstein JA, Mehta L, Pica MC, O'Neill WW. Resolution of refractory no‐reflow with intracoronary epinephrine. Catheterization and cardiovascular interventions. 2002;57(3):305-9.
Yassin I, Ahmed A, Abdelhady G. Distal intracoronary delivery of epinephrine versus verapamil to prevent no-reflow during primary percutaneous coronary intervention: a randomized, open-label, trial. Cardiol Vasc Res. 2021;5(5):1-6.
Navarese EP, Frediani L, Kandzari DE, Caiazzo G, Cenname AM, Cortese B, et al. Efficacy and safety of intracoronary epinephrine versus conventional treatments alone in STEMI patients with refractory coronary no‐reflow during primary PCI: The RESTORE observational study. Catheterization and cardiovascular interventions. 2021;97(4):602-11.
Hochholzer W, Trenk D, Frundi D, Blanke P, Fischer B, Andris K, et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation. 2005;111(20):2560-4.
Hafez M, Ghazawy A, Zahran M. Intracoronary verapamil vs. intracoronary epinephrine in the management of coronary no reflow during primary percutaneous coronary intervention. Interv Cardiol. 2021;14:436-43.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 S KHAN, SU REHMAN, W SAJJAD, S BEGUM, R YASMIN, IU ADIL
![Creative Commons License](http://i.creativecommons.org/l/by-nc/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.